C21 – IPF fibrosis

C21 is a first-in-class orally available low molecular weight angiotensin II type 2 receptor agonist (ATRAG).

The novel and multimodal mechanism of action of C21 targets the underlying fibrosis in IPF by stimulating the protective arm of the renin-angiotensin system. Consequently, there is an upstream effect in terms of promoting alveolar repair and maintenance of alveolar integrity thereby reducing fibrosis formation, stabilizing disease, and increasing lung capacity.

The AIR trial is a phase 2a multi- center open label single arm 24-week trial with the addition of a 12-week extension study evaluating the safety and efficacy of C21 in patients with IPF.

Read more about the AIR trial: Clinicaltrials.gov